The results revealed that the TPL2 overexpression rates in Normal, FCC, DCIS, and IDC groups were 36.7% (11/30), 43.3% (13/30), 76.7% (23/30), and 65% (52/80), respectively. The gene discussed is MAP3K8; the disease is ductal breast carcinoma in situ.